Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients

Matevska-Geshkovska, Nadica; Staninova-Stojovska, Marija; Kapedanovska-Nestorovska, Aleksandra; Petrushevska-Angelovska, Natalija; Panovski, Milco; Grozdanovska, Biljana; Mitreski, Nenad; Dimovski, Aleksandar

doi:10.2147/pgpm.s172467

Cited by 3 publications

(7 citation statements)

References 47 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The included studies were published between 2013 and 2021 [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. Most were cohort studies [ 20 , 21 , 22 , 23 , 24 , 26 , 28 , 29 , 30 , 31 ].…”

Section: Resultsmentioning

confidence: 99%

“…Most were cohort studies [ 20 , 21 , 22 , 23 , 24 , 26 , 28 , 29 , 30 , 31 ]. Clinical data collection was mainly prospective [ 20 , 21 , 23 , 27 , 28 , 29 , 30 ]. Eight studies were conducted in populations of European ancestry [ 20 , 21 , 23 , 24 , 25 , 26 , 29 , 31 ], two in the Indian population [ 28 , 30 ], and one in patients of Asian origin [ 32 ].…”

Section: Resultsmentioning

confidence: 99%

“…Eight studies were conducted in populations of European ancestry [ 20 , 21 , 23 , 24 , 25 , 26 , 29 , 31 ], two in the Indian population [ 28 , 30 ], and one in patients of Asian origin [ 32 ]. In two studies, the ethnicity of the study population was not specified [ 22 , 27 ]. Regarding the treatment regimens studied, five studies evaluated patients under treatment with capecitabine in combination with other neoplastic agents [ 23 , 24 , 28 , 29 , 30 ], three with capecitabine as monotherapy [ 20 , 27 , 31 ], and five with capecitabine as monotherapy and in combination [ 21 , 22 , 25 , 26 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

“…In two studies, the ethnicity of the study population was not specified [ 22 , 27 ]. Regarding the treatment regimens studied, five studies evaluated patients under treatment with capecitabine in combination with other neoplastic agents [ 23 , 24 , 28 , 29 , 30 ], three with capecitabine as monotherapy [ 20 , 27 , 31 ], and five with capecitabine as monotherapy and in combination [ 21 , 22 , 25 , 26 , 32 ]. Five studies only investigated capecitabine PD-related genes [ 20 , 24 , 27 , 29 , 32 ], two only investigated PK-related genes [ 23 , 28 ], and six studied genes related to both [ 21 , 22 , 25 , 26 , 30 , 31 ].…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the treatment regimens studied, five studies evaluated patients under treatment with capecitabine in combination with other neoplastic agents [ 23 , 24 , 28 , 29 , 30 ], three with capecitabine as monotherapy [ 20 , 27 , 31 ], and five with capecitabine as monotherapy and in combination [ 21 , 22 , 25 , 26 , 32 ]. Five studies only investigated capecitabine PD-related genes [ 20 , 24 , 27 , 29 , 32 ], two only investigated PK-related genes [ 23 , 28 ], and six studied genes related to both [ 21 , 22 , 25 , 26 , 30 , 31 ]. Eight studies evaluated the influence of SNPs on the incidence and severity of capecitabine-induced toxicity [ 21 , 22 , 23 , 25 , 26 , 28 , 31 , 32 ], three assessed the influence of SNPs on the effectiveness of capecitabine-based therapy [ 24 , 27 , 30 ], and two evaluate the influence of SNPs on both toxicity and effectiveness [ 20 , 29 ].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

Cura

Pérez-Ramírez

Sánchez-Martín

et al. 2023

Cancers

View full text Add to dashboard Cite

The aim of this systematic review was to provide a comprehensive overview of the literature published in the last decade on the association of single-nucleotide polymorphisms in genes involved in the pharmacodynamic and pharmacokinetic pathways of capecitabine with treatment outcomes among colorectal cancer patients. A systematic search of the literature published in the last 10 years was carried out in two databases (Medline and Scopus) using keywords related to the objective. Quality assessment of the studies included was performed using an assessment tool derived from the Strengthening the Reporting of Genetic Association (STREGA) statement. Thirteen studies were included in this systematic review. Genes involved in bioactivation, metabolism, transport, mechanism of action of capecitabine, DNA repair, and folate cycle were associated with toxicity. Meanwhile, genes related to DNA repair were associated with therapy effectiveness. This systematic review reveals that several SNPs other than the four DPYD variants that are screened in clinical practice could have an impact on treatment outcomes. These findings suggest the identification of future predictive biomarkers of effectiveness and toxicity in colorectal cancer patients treated with capecitabine. However, the evidence is sparse and requires further validation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

Cura

Pérez-Ramírez

Sánchez-Martín

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer

Bhattacharya

2023

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Investigation of Cervical Tumor Biopsies for Chromosomal Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in HIV-1/HPV Co-infected Women

et al. 2019

View full text Add to dashboard Cite

Background: A subgroup of women who are co-infected with human immunodeficiency virus type 1 (HIV-1) and human papillomavirus (HPV) progress rapidly to cervical disease regardless of high CD4 counts. Chromosomal loss of heterozygosity (LOH) and microsatellite instability (MSI) are early frequent genetic alterations occurring in solid tumors. Loss of an allele or part of a chromosome can have multiple functional effects on immune response genes, oncogenes, DNA damage-repair genes, and tumor-suppressor genes. To characterize the genetic alterations that may influence rapid tumor progression in some HIV-1-positive women, the extent of LOH and MSI at the HLA II locus on chromosome 6p in cervical tumor biopsy DNA samples with regard to HIV-1/HPV co-infection in South African women was investigated.Methods: A total of 164 women with cervical disease were recruited for this study, of which 74 were HIV-1-positive and 90 were HIV-1-seronegative. DNA from cervical tumors and matched buccal swabs were used for analyses. Six fluorescently-labeled oligonucleotide primer pairs in a multiplex PCR amplification were used to study LOH and MSI. Pearson chi-squared test for homogeneity of proportions using an exact p value, a two-proportion Z-score test, ROC curves and a logistic regression model were used for statistical analyses. All p-values were corrected for false discovery rate (FDR) using the Benjamini-Hochberg test and the adjusted p-values (q-values) were reported. All tests were significant when both p and q < 0.05.Results: Tumor DNA from HIV-1/HPV co-infected women demonstrated a higher frequency of LOH/MSI at the HLA II locus on chromosome 6p21.21 than tumor DNA from HIV-1-seronegative women (D6S2447, 74.2 vs. 42.6%; p = 0.001, q = 0.003), D6S2881 at 6p21.31 (78.3 vs. 42.9%; p = 0.002, q = 0.004), D6S2666 at 6p21.32 (79 vs. 57.1%; p = 0.035, q = 0.052), and D6S2746, at 6p21.33 (64.3 vs. 29.4%; p < 0.001, q < 0.001), respectively.Conclusions: HPV infection alone can induce LOH/MSI at the HLA II locus in cervical tumor DNA, whereas HIV-1 co-infection exacerbates it, suggesting that this may accelerate cervical disease progression in a subgroup of HIV-1-positive women.

show abstract

Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients

Cited by 3 publications

References 47 publications

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer

Investigation of Cervical Tumor Biopsies for Chromosomal Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in HIV-1/HPV Co-infected Women

Contact Info

Product

Resources

About